CI

Group critical illness is experiencing a positive period of steady growth. Fiona Murphy takes a closer look at the market.

I am a group risk consultant. GRID has published industry claim statistics that show the types and amounts of claim, as well as showing group risk claim payout rates for the first time. Can I use these with my corporate clients? If so, how, and what kind...

There is nowhere more ‘front line' than a claims department, and recent years have seen great improvements. Craig Colton expects there will be more to come.

Individual critical illness saw a relentless pace of change last year. But has the industry gone far enough? Fiona Murphy investigates.

There is a chance that not only will stem cell therapy enter the mainstream, but that IFAs will be advising on it. As a pilot opens in the UK, Sue Wilkinson outlines the case.

In our recent COVER 360 research, our adviser- respondents said the children's cover element of critical illness cover is the second least important reason in recommending the product. However, this is a high reason for claim. Why is take-up and interest...

CIExpert is frequently asked why the PruProtect plan is not included within the comparison section of the site. Alan Lakey explains.

We saw a lot of changes to critical illness (CI) products last year. Do you think these changes presented a meaningful difference, or was it a case of change for change's sake?

Learn about Aegon's critical illness cover.

Term assurance is the most black and white protection policy. Have we seen any colour in the market over the past year? Fiona Murphy investigates.